The acamprosate group demonstrated significantly superior efficacy versus the placebo group on the primary endpoint : the proportion maintaining complete abstinence in the acamprosate group was @ % ( @/@ subjects ) , compared with @ % ( @/@ subjects ) in the placebo group ( P = @ ) .